



Long-Term Safety and Efficacy of Azetukalner, a Novel, Potent KV7 Potassium Channel Opener, in Adults With Focal Epilepsy: $\geq$ 48-Month Interim Analysis of the Ongoing 7-Year X-TOLE Open-Label Extension

September 7, 2026

Congress: European Epilepsy Congress (September 6, 2026)

Authors: French JA, et al.

Encore of AES 2025